Life Sciences Archive » July, 2006

Life Sciences - July, 2006

121 articles

• Digene Wins Arbitration Ruling Over HPV License
• In Reversal, FDA Opens Door To Morning-After Pill
• Boston Scientific, St. Jude Settle Four Patent Suits
• ImClone Motion Denied In Erbitux Case
• FDA Breast Implant Decisions Cleared By Senate Panel
• State Attorneys General Reject Revised Plavix Deal
• FTC Probes Mylan Over Provigil Settlements
• Smith & Nephew Blames Sales Rep In Antitrust Probe
• Pfizer Puts General Counsel In Charge
• Trial Begins In Latest Wyeth Diet Drug Case
• SEC Adds Defendants To Insider-Trading Suit
• Biomet Says DoJ Scales Down Antitrust Probe
• Intermune Eyes Settlement Over Off-Label Marketing
• SEC Settles Case Over Insider Trading On FDA Decision
• FBI Raids Bristol-Myers Over Plavix Deal
• Zimmer Tries To Clear Name In Price-Fixing Scandal
• DOJ Launches Criminal Probe Into Plavix Deal
• J&J Unit Takes On Wyeth's Effexor In Patent Suit
• Abbott Wins Antitrust Challenge Over HIV Drug Cocktail
• Bill Would Move Vaccine Safety Out Of CDC
• Universities, Hospitals Join Patent Litigation Bonanza
• Korea Pushes Drug-Pricing Law
• Judge Tosses Patent Case Against Stryker
• Tyco Sticks Applied Medical With Fresh Patent Suit
• Invitrogen Gets Biotech Patent Win In Jury Trial
• Eye Care Company Says It's Not Eyeing Rival's Patent
• Upsher-Smith, Unigene Sue Apotex After ANDA Filing
• Orthopedic Industry Braces For Possible Storm
• Jury Awards $5M In Infant Tylenol Poisoning Case
• SEC Investigates Par Pharmaceutical
• RxUSA Files New Suit Against Wholeseller
• FDA Bolsters Rules On Outside Advisors
• America's Top Health Litigators: Drinker Biddle & Reath
• N.J. High Court Mulls Vioxx Class Status; $30B At Stake
• Swiss University Sues Synthes In Pilot Case
• Van Der Moolen Washes Its Hands Of Stock Fraud
• Plavix Ruling From Attorneys General Imminent
• Early Approval For Astra's Asthma Drug Stuns Analysts
• Orthopedic Company Antitrust Subpoena "Narrowed"
• Brinks Hofer Opens Doors In Salt Lake City
• Roche Rallies In Wake Of Enzo Biochem Ruling
• Political Pressure-Cooker Mentality At FDA: Report
• Erbitux Trial Awaits Judge's Decision
• Senators Take Aim At Authorized Generics
• Amgen Criticizes Roche's Anemia Study
• America's Top Health Litigators: Reed Smith
• Par Pharmaceutical Hit With Securities Suits
• Elan Files Patent Suit Over Breast Cancer Drug
• UBS Says Bankrupt Company Is Overvalued By $100M
• America's Top Health Litigators: McDermott Will & Emery
• Suit Alleges Conspiracy Among Drug Cos., Wholesalers
• FTC Commissioner Slams Authorized Generics
• ImClone, Merck Reach Deal Over Erbitux
• Fourth Circuit Rejects Another Authorized Generics Challenge
• Court Issues Markman Ruling In Enzo Biochem Case
• Fed. Circuit Affirms University's Grip On Allergy Patent
• E-mails Question FDA Review Process For Ketek
• Court Finds Non-Infringement In Alaris, ICU Case
• America's Top Health Litigators: Sidley Austin
• FDA OKs Medtronic's New Glucose Monitor
• America's Top Health Litigators: Jones Day
• Jury Denies Baxter's $87M Bid In Dialysis Dispute
• Settlement Gets To Heart Of Stent Lawsuit
• Bio-Rad Settles Lengthy Licensing Dispute
• Six Years After Wyeth Debacle, Birth Control Rod OK'd
• Medtronic To Pay $40M To Settle Kickback Charges
• Court Upholds Blood Pressure Drug Patent
• America's Top Health Litigators: Fitzpatrick, Cella
• Royal Bank Of Scotland Nearing Enron Settlement
• Eli Lilly Gets Green Light For New Use Of Gemzar
• Generic Drug Maker Gets Chapter 11 OK
• Roche, Sanofi Settle Australian Vitamins Cartel Action
• Pfizer Stuck With 17 New Lipitor Suits
• Orthopedic Makers Conspired To Fix Prices, Suit Claims
• FDA Opts To Fast Track Constipation Drug
• Ex-Van Der Moolen Specialists Convicted Of Fraud
• America's Top Health Litigators: McCarter & English
• FDA Calls Off Closed Hearing On Blood Substitute
• Tax Patents: Ball Is In Your Court, PTO Tells Congress
• Lawmakers Try To Put Brakes On Medicare Overhaul
• Class Action Adds To Drug Maker's Troubles
• In Blow To Ivax, Judge Upholds Lexapro Patent
• Health Courts? No Thanks, Say Trial Lawyers
• Merck Wins New Jersey Vioxx Case
• FDA Draws Fire For Closed Hearing On Blood Substitute
• America's Top Health Litigators: Kaye Scholer
• Generic Drug Settlement Prompts More FTC Scrutiny
• New Study Supports Biotech Fears Over USPTO Changes
• British Enron Trio Depart For Texas Trial
• Law Firm Profile: Banner & Witcoff Ltd.
• America's Top Health Litigators: Shook, Hardy & Bacon
• Merck Strategy Still Murky As Jury Mulls Vioxx Claims
• Judge Tosses Sandoz' Injunctive Bid Over Zocor
• SeraCare, Shareholders Agree To Exclusivity Deal
• FDA Backs Boston Scientific's Recall Of Heart Devices
• Senate Votes To Allow Access To Canadian Drugs
• Forest Sues To Keep Generic Lexapro Off Market
• Chemical Cos. Settle Spat Over Cystic Fibrosis Drug
• Dusa Targets Chemical Supplier, Physicians In Suits
• Lawyer: Heart Attack Caused By Bad Health, Not Vioxx
• FDA Slacking On Post-Approval Follow-Up: Report
• America's Top Health Litigators: Dechert
• Medegen Unit Hits ICU Medical With Suit
• Lawmakers Debate NatWest Three Extradition
• Under Vioxx Fire, Merck Faces Fosamax Claims Too
• FTC Scrutiny Casts Doubt On Plavix Settlement
• Amgen Loses Battle In Anemia War With La Roche
• Extradition Day Arrives For U.K. Bankers
• Lawsuit Targets Director Of USPTO
• Lord Bissell's Health Care Practice Balloons
• As Drug Risks Mount, Senators Put Pressure On FDA
• 10 Stand-Out Firms Win Industry's Confidence
• University, Nektar Settle Patent Feud For $25M
• J&J Subsidiaries Fight Back Generic Challenge
• FTC Detects Cancer Screening Monopoly
• Citizen Petitions Come Under Fire In Pharma War
• Doctor Testifies Merck Knew Of Vioxx Risk
• Ruling Sets Up Patent Battle Over Growth Treatment
• Device Makers Settle Suit Over Incontinence Treatment
• The Gathering Storm: Supreme Court Case Promises Change in Patent Law
• British Business Leaders Brassed Off Over Extradition